RT Journal Article
T1 Hydrogenosome metabolism is the key target for 1 antiparasitic activity of resveratrol against 2 Trichomonas vaginalis
A1 Mallo Seijas, Natalia
A1 Lamas Fernández, Jesús
A1 Leiro Vidal, José Manuel
AB Metronidazole (MDZ) and related 5-nitroimidazoles are the recommended drugs for treatment of trichomoniasis, a sexually transmitted disease caused by the protozoan parasite Trichomonas vaginalis. However, novel treatment options are needed, as recent reports have claimed resistance to these drugs in T. vaginalis isolates. In this study, we analyzed for the first time the in vitro effects of the natural polyphenol resveratrol (RESV) on T. vaginalis. At concentrations of between 25 and 100 μM, RESV inhibited the in vitro growth of T. vaginalis trophozoites; doses of 25 μM exerted a cytostatic effect, and higher doses exerted a cytotoxic effect. At these concentrations, RESV caused inhibition of the specific activity of a 120-kDa [Fe]-hydrogenase (Tvhyd). RESV did not affect Tvhyd gene expression and upregulated pyruvate-ferredoxin oxidoreductase (a hydrogenosomal enzyme) gene expression only at a high dose (100 μM). At doses of 50 to 100 μM, RESV also caused overexpression of heat shock protein 70 (Hsp70), a protective protein found in the hydrogenosome of T. vaginalis. The results demonstrate the potential of RESV as an antiparasitic treatment for trichomoniasis and suggest that the mechanism of action involves induction of hydrogenosomal dysfunction. In view of the results, we propose hydrogenosomal metabolism as a key target in the design of novel antiparasitic drugs.
PB ASM Journals
SN 0066-4804
YR 2013
FD 2013-05-13
LK https://hdl.handle.net/10347/45935
UL https://hdl.handle.net/10347/45935
LA eng
NO Mallo N, Lamas J, Leiro JM. 2013. Hydrogenosome Metabolism Is the Key Target for Antiparasitic Activity of Resveratrol against Trichomonas vaginalis. Antimicrob Agents Chemother 57. https://doi.org/10.1128/aac.00009-13
DS Minerva
RD 23 abr 2026